Jennerex biotherapeutics inc
WebJul 19, 2024 · Adina Pelusio, Ph.D., brings more than 15 years of experience in drug development, most recently as the Vice President, Clinical Operations at SillaJen Biotherapeutics (formerly Jennerex, Inc ... WebMay 24, 2013 · Jennerex Biotherapeutics Inc., which develops oncolytic immunotherapies for solid tumors, said it has raised $21.6 million in a private placement.
Jennerex biotherapeutics inc
Did you know?
WebNov 9, 2024 · Adina Pelusio. “Kerensa is an experienced clinical research profession and project manager. Her expertise provided valuable insight and efficiencies within the clinical operations group. Her ... WebNov 26, 2013 · Jennerex is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers.
WebJanke previously served in various consulting roles in 2013-2014 including: Senior Director of Corporate Projects & Alliance Management at SillaJen, Inc. (formerly Jennerex Biotherapeutics Inc.), a biotech company focused on engineering and developing oncolytic immunotherapeutics, and Director, Clinical Research & Development—Strategy and … WebMay 13, 2013 · Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company, has received the orphan drug designation from the United States Food and Drug Administration (FDA) for Pexa-Vec (JX-594, pexastimogene devacirepvec) for the …
WebExperienced Clinical Business Manager with a demonstrated history of working in the Pharmaceutical and Medical industry. Skilled in Sales, Biotherapeutics, Customer Relationship Management (CRM ... WebJennerex Biotherapeutics, Inc., San Francisco, CA, USA 3 Division ofTumorVirology, German Cancer Research Center (DKFZ), Heidelberg, Germany Philippe Fournier, DKFZ, Germany Reviewed by: Valery Grdzelishvili, University of North Carolina at Charlotte, USA Volker Schirrmacher, DKFZ, Germany Yong Lu, Cleveland Clinic Foundation, USA Research ...
WebSep 6, 2011 · Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.
Web201 Mission Street, Suite 1380 94105 San Francisco USA +1415281-8886 jennerex.com Profile Products Contact About Jennerex Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, … prisma mountain lakesWebJennerex Biotherapeutics, Inc. develops and commercializes oncolytic immunotherapies for solid tumors. The Company offers products are designed to attack cancer tumors through synergistic and ... prisma muistikorttiWebJames has over 20 years of preclinical and clinical experience in the field of gene and immunotherapy. James was previously CMO at Turnstone Biologics and Jennerex Biotherapeutics / SillaJen where he oversaw global clinical development for oncolytic virus therapies. Prior to Jennerex, he was Associate Director of Clinical Research at Cell Genesys. prisma mylly kotiinkuljetusWebMay 13, 2013 · Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company, has received the orphan drug designation from the United States Food and Drug Administration (FDA) for Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of hepatocellular carcinoma (HCC, commonly referred to as liver cancer). prisma munalukkoWebNov 26, 2013 · Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and South Korea. Pexa-Vec is partnered in Europe with Transgene, a member of the ... prisma muovilautanenWebJennerex Biotherapeutics has raised a total of $56.1M in funding over 7 rounds. Their latest funding was raised on May 23, 2013 from a Private Equity round. Jennerex Biotherapeutics is funded by Ottawa Regional Cancer Foundation. Funding … prisma muumi lasten aterinsettiWebMar 20, 2012 · Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. prisma monitoimitulostin